We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bellevue Healthcare Trust Plc | LSE:BBH | London | Ordinary Share | GB00BZCNLL95 | RED ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.40 | 0.28% | 142.00 | 1,021,609 | 16:35:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 141.80 | 142.80 | 142.60 | 140.40 | 140.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | -107.16M | -121.04M | -0.2617 | -5.45 | 659.65M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:45:18 | O | 197 | 141.98 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/4/2024 | 10:09 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 17/4/2024 | 10:25 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 16/4/2024 | 09:52 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 15/4/2024 | 10:19 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 12/4/2024 | 10:09 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 11/4/2024 | 10:06 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 10/4/2024 | 09:42 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 10/4/2024 | 07:00 | UK RNS | Bellevue Healthcare Trust PLC Company Secretary and Registered Office.. |
| 09/4/2024 | 09:44 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
| 08/4/2024 | 09:41 | UK RNS | Bellevue Healthcare Trust PLC Net Asset Value(s) |
Bellevue Healthcare (BBH) Share Charts1 Year Bellevue Healthcare Chart |
|
1 Month Bellevue Healthcare Chart |
Intraday Bellevue Healthcare Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/3/2024 | 15:12 | ::: B B HEALTHCARE TRUST ::: | 139 |
| 12/7/2006 | 16:01 | Biotech Holders: the last to Run? | 15 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:45:43 | 141.98 | 197 | 279.70 | O |
| 16:45:11 | 141.98 | 27,868 | 39,566.71 | O |
| 16:45:11 | 141.64 | 83 | 117.56 | O |
| 16:44:46 | 141.19 | 5,627 | 7,944.54 | O |
| 16:31:23 | 141.59 | 7,807 | 11,053.78 | O |
| Top Posts |
|---|
Posted at 18/4/2024 09:20 by Bellevue Healthcare Daily Update Bellevue Healthcare Trust Plc is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker BBH. The last closing price for Bellevue Healthcare was 141.60p.Bellevue Healthcare currently has 462,588,550 shares in issue. The market capitalisation of Bellevue Healthcare is £659,651,272. Bellevue Healthcare has a price to earnings ratio (PE ratio) of -5.45. This morning BBH shares opened at 140.40p |
Posted at 14/3/2024 15:12 by alter ego I struggled to find out when the dividend will be paid and when it goes ex div. BBH Corporate Calendar didn't say so I contacted IR. Ex Div on 9 May, paid on 31 May. Apparently it's on page 78 of the Annual Report. I've suggested they might make it a bit more visible and they said yes, they would look at that. |
Posted at 12/3/2024 19:28 by xtrmntr Bellevue Healthcare (BBH) has extended its run of underperformance, with its bias towards small- and mid-cap stocks meaning it has now lagged its benchmark since inception in 2016.The 'classical defensive attributes' of the healthcare sector failed to entice investors for yet another year, said Paul Major, who manages the £699m fund with Brett Darke.The MSCI World Healthcare index fell 1.8% in 2023, underperforming the MSCI World index by 14.8%, which Major said was 'almost a mirror image of what happened in full-year 2022' and marked 'the worst relative annualised performance over this period in the 23 years'.As investors shunned healthcare despite the economic woes faced by markets, the investment trust saw its net asset value (NAV) sink 12.7% in the year ended 30 November 2023 versus a 7.1% slide in the MSCI World Healthcare benchmark. This has challenged the fund's track record, and since inception in December 2016, NAV total returns are now 103% versus 127% for the benchmark.Major said the fall in the year to 30 November was due to several factors, including larger companies not being as defensive as hoped for as mega-cap bellwethers Pfizer and Sanofi cut earnings forecasts. There was also the 'nebulous perception' of research and development disappointments and a lack of mergers and acquisitions.The 'outsize' factor contributing to underperformance over the year was the fund's bias towards smaller companies as the 'past few years have seen investors hiding in the relative safe haven of larger, more liquid and typically more diversified companies'.'Such companies tend to be older and more mature, so less at the mercy of debt and equity markets for additional funding and thus less sensitive to interest rates,' said Major.'They are also easier to exit if the market does look like it is going down and investors wish to reduce equity exposures.'Major added that the 'compression' seen in small- and mid-cap healthcare stocks was 'far beyond anything that could be justified' and the positive trajectory of the same stocks in December 2023 and January 2024 after the end of the results period 'attests to the arbitrary and egregious nature of the devaluation that investors have witnessed over the past two years'.To back up his point, Major doubled down on his allocation to smaller companies, ending the year with 3% less exposure to mega- and large-cap companies and increasing at the other end of the size spectrum.The already large exposure to the US was also increased and now sits at 95%, as Major exited Europe and 'rest of world'. And valuations in China continued to experience 'significant pressure' due to a lacklustre post-Covid recovery and overhang from an anti-corruption drive.The portfolio started the year with 29 positions and ended with 27 after five additions and seven exits in another low turnover year.One holding Major reduced mid-year was Apellis Pharmaceuticals as the shares reached fair value but shortly after it slumped more than 70% 'on concerns about side effects for its key drug Syfovre (an eye injection used to treat geographic atrophy)'. 'We felt this was an overreaction so we scaled up the position and rode the recovery to considerable profit,' he said. 'We have since been taking profits again.'Major added that the market has been 'prone to overreactions on the downside' in the past two years and said last summer was marked by the 'frenzy' around the use of GLP-1 obesity drugs that gripped the market and divided healthcare stocks into 'a perceived binary grouping of obesity winners and losers'.In a bid to take advantage of these mispricings in the market, Major has been increasing allocation to tools, healthcare IT and healthcare technology, while reducing exposure to diversified therapeutics.The trust has enjoyed some respite from underperformance since the financial year-end, with the shares up nearly 9% in the past three months, in line with the index but ahead of the underlying 6.9% rise in the portfolio. That's left the shares standing 5.1% below net asset value, narrower than their 7% one-year average discount.He remained committed to investing in 'healthcare change' and said the current model is 'neither scalable nor financially sound' enough to deal with an ageing population and the demand for better products for more people.'If we cannot bend the cost curve and change the delivery paradigm, the services will need to be cut or the system will go bankrupt. Ergo, healthcare must change,' he said. 'There is no alternative.' |
Posted at 04/3/2024 20:31 by speedsgh Annual Financial Report - Recent trading and outlook In these fast moving and macro-oriented times, we continue to recommend that investors rely upon the detailed and discursive monthly factsheets for an up-to-date view of the outlook. These can be found on the Company's website1. We are pleased to report that the Company's performance in the three months to the end of February 2024 has been positive on a relative and absolute basis and the macroeconomic situation is coalescing around a more constructive, narrower range of outcomes, even if the geopolitical circumstances remain febrile. It bears repeating that our strategy of investing in `healthcare change' remains a powerful and compelling one. Healthcare continues to be the secular growth story of our age. Recession or not, there are ever more people and they are ageing. More and more countries are becoming developed economies and scientific progress continues to open up new avenues to relieve the burden of human suffering, raising expectations of what products and services will be available to this ever-greater number of people. However, society needs to pay for all of this and the current model is neither easily scalable nor financially sound. If we cannot bend the cost curve and change the delivery paradigm, the services will need to be cut or the system will go bankrupt. Ergo, healthcare must change. There is no alternative. We have already seen profound changes implemented since the pandemic. The tools, products and services that are enabling the re-imagining of healthcare can be accessed through the public equity realm, creating a persuasive investment opportunity. The past few years may have been very challenging, but the fundamentals remain very attractive. |
Posted at 13/2/2024 15:45 by speedsgh Bellevue Healthcare Trust update with Doceo - ... Brett Darke, co-manager of the Bellevue Healthcare Trust, explains why the team believe that now is a compelling time to be seeking opportunities in the mid cap healthcare space. Darke observes that, although valuations have fallen to new lows, the market expectations for portfolio company revenues remain unchanged. While interest rates do play a meaningful role in performance, Darke points to history to explain that it is possible to invest in mid cap healthcare growth stocks in a tightening rate environment. |
Posted at 12/1/2024 11:22 by speedsgh Target dividend of 5.02p for FYE 30/11/24 (2.52p interim payable Aug/Sept 24; 2.52p final payable Mar/Apr 25). Reduction of 15.9% on 5.99p for FYE 30/11/23...Target Total Dividend - 2.995p final payment for FYE 30/11/23 (not yet officially declared) to be paid Mar/Apr 24. |
Posted at 22/12/2023 06:23 by takeiteasy Coming back to the quality end of the listed space. As we have noted inprevious factsheets, the only way to back-solve for the de-rating that we have seen across our portfolio would be to apply double-digit discount rates to everything, with some companies well into the teens. Yields on 30-year US Treasuries have risen ~300bp over the past two years (from ~200bp to ~500bp at the end of October), which is simply not enough to explain the de-rating we have seen. Indeed, this must imply a very material increase in the ‘equity risk premium’ for healthcare stocks. Investors need to decide for themselves whether or not a material increase in the ERP is justified. If it isn’t, and if you agree with the first point that the fundamentals of healthcare have not changed, then the patient investor should be piling into these de-rated small and mid-cap healthcare companies. A quote from the BBH monthly fact sheet recently out - perhaps one of the more incisive commentaries of the state of the markets and biotech more specifically. It has been a dreadful few years as the last post confirms - things have got so bad that there is little expectation for a decent recovery..so are getting lower rates now (UST 30 year is now 4% and not 5% as noted above) and hopes of a soft landing in US in 2024..will that be enough to start things off.. dyor and no advice intended etc www.bellevuehealthca Bellevue Healthcare Trust PLC portfolio manager Paul Major speaks to Proactive's Thomas Warner about what he calls "the strangest year" in his career and "the worst relative performance for healthcare in 30 years." 19.12.2023 - Paul Major |
Posted at 10/11/2023 13:45 by speedsgh The latest factsheet contains an empassioned defence of BBH's strategy amid the continued underperformance of the trust. I have to say that I agree with the managers' analysis of the reasons for the underperformance... or is that just my confirmation bias? Time will tell but I suspect that in the goodness of time the current share price will be viewed as having been an excellent opportunity. I have acted accordingly. AIMHO |
Posted at 02/11/2023 15:23 by speedsgh Some interesting discussion on BBH and their looming annual voluntary redemption offer in the latest Money Makers podcast...From 49m18s to 53m22s |
Posted at 25/5/2023 18:28 by speedsgh Is it time to buy healthcare? - The Armenian oil magnate Calouste Gulbenkian was, when confronted with points others believed would hurt his business, fond of issuing a simple retort; “The dogs bark, the caravan moves on.” It might be easy to dismiss this as flippancy, but given he survived close to 70 years in the oil industry and died the world’s wealthiest man, it’s probably fair to assume he had a good idea of what mattered and what didn’t. Whether or not we’re quite as astute as Gulbenkian is up for debate, but his favourite retort does come to mind when looking at many listed healthcare companies today. Over the past 18 months, we’ve seen many firms in the sector see substantial drawdowns, albeit after a period of stronger performance that started following the onset of the pandemic. Some investment trusts that invest in the healthcare industry have managed to weather this storm better than others. However, the average share price total returns for the AIC’s Biotechnology and Healthcare as a whole were negative for the 12 months to 26/04/2023. Bellevue Healthcare’s (BBH) returns at that time were slightly down in NAV terms, with a fall of 1.7%. The trust’s shares fell further, with a 6.4% drawdown on a total return basis. As that suggests, the trust has seen its discount widen substantially as a result. Having traded at a 6% premium in May of last year, something that enabled the trust to issue new equity, the trust’s shares are now sitting at a nearly 8% discount to NAV. This is among the lowest levels the trust’s shares have traded at relative to NAV since launch. It is also far below the five-year discount average of 0.2%. It is easy to see how the events of the last 18 months have made investors feel uneasy. The war in Europe and the highest levels of inflation we’ve seen since the 1970s do not make for the most relaxing of backdrops in which to invest. But on a macro level; it is hard to see what has changed for the healthcare sector. Reports in January that China’s population is declining for the first time in decades were another reminder that the world is getting older. Readers will know that this is not a new trend. In 2017, the United Nations published a report noting that the global population of people over 60 had risen to 962m – up from 382m in 1980. The World Health Organisation believes this dynamic is likely to result in a substantial change in the world’s demographics over the next 25 years, with the proportion of people over 60 almost doubling from 12% in 2015 to 22% by 2050. We can see the impact this is having on healthcare spending. For example, in the UK, total spending on healthcare rose from £78.9bn in 2000 to £222.7bn in 2019, or 5.6% on average annually. GDP rose from £1.62trn to £2.24trn, equivalent to 1.7% per year, over the same period. More than 80% of that spending normally comes from the state, and a similar picture is evident across the world. As readers can likely infer, this has the potential to create a circular problem. More GDP growth is needed to fund rising healthcare costs. But the lack of spending in other parts of the economy, as well as higher taxes needed to fund those increasing healthcare costs, arguably crimp that growth. This plays into one of the key themes we see in the BBH portfolio, namely that there are innovative companies attempting to address this problem by providing new solutions to existing healthcare problems. It also partly explains the company’s recent performance, as these are the sorts of companies that have attracted more investor concern over the past 18 months. Partly that’s because of valuations, but it’s also due to fears that earlier stage firms won’t be able to raise money or make it to profitability. There are a couple of points that should allay fears here. One is that BBH managers John Major and Brett Darke have repeatedly noted that, even if the discount rate used to value portfolio companies were to rise markedly, they would still think they were fairly valued. Those are not just idle words, as they have been adding to the portfolio as well as to existing positions over the past 18 months. Both managers have also made substantial additions to their own holdings in BBH during that time. And in the first quarter of this year, two companies in the portfolio raised money via equity issuance rather than debt. In both instances, the two issuances were oversubscribed, a sign that plenty of institutional investors still believe these companies offer the potential for long-term returns. That doesn’t mean it’s going to be smooth sailing and that we won’t see further volatility in the near term. But the secular trends described above combined with the managers’ stock picking abilities make it plausible we’ll see returns smooth out over the long-term. Or, as Gulbenkian might have it, the dogs bark, the caravan moves on. Login to read the full article... |
Posted at 12/8/2022 21:08 by xtrmntr The managers of investment trust Bellevue Healthcare are confident the future of the global healthcare industry is a bright one. Ageing populations across the world and the exponential growth in chronic illnesses mean demand for healthcare services is here to stay, irrespective of any economic downturn. So confident are the management team that since the start of the year, they have used £80million of low-cost borrowings to increase the trust's holdings in equity markets. The two individuals overseeing the £1billion portfolio Paul Major and Brett Darke have also been busy buying more personal shares in the trust, a sure-fire sign that they believe the outlook is more positive than negative.'Of course, as an investor in equities, you can't dismiss the Putin factor,' says Major, 'Or for that matter, geopolitical tensions in the South China Sea. ''It explains why we have kept some powder dry just in case something happens which causes share prices to plunge sharply and suddenly. If that happened, we would use the borrowings we have yet to employ to buy even more shares in the companies we own. 'The fact remains that many of the companies we invest in are super-resilient businesses that will keep on growing. They provide a degree of certainty in an uncertain world. The trust is invested in 29 healthcare stocks, most listed in the United States. 'We keep an eye on some 250 companies,' says Major. 'Most are small to medium-sized businesses doing extraordinary things in the healthcare sector. But their share prices have been hit by the general slide in US equity values over the past nine months.' Bellevue's numbers confirm this. Over the past year, the trust has recorded losses of nearly 9 per cent. This compares with five-year gains of 73 per cent. 'Our job is to find companies that can deliver healthcare solutions, whether it is in disease prevention, diagnosis, treatment or recovery,' says Major. Among the trust's top 10 holdings is CareDx, a US company that provides at-home testing kits to people who have had a major organ transplant. 'The tests help reduce the risk of organ rejection,' says Major. 'They are able to identify any adverse impact on the replacement organ as a result of the drugs being used and any weakening of the immune system that could trigger other conditions.' The investment trust has had a holding in CareDx on and off over the years, but reinvested in the company in September last year. Another big fund stake is in Axonics, a business that has developed a small electronic implant that helps people who suffer from involuntary leakage of the bladder or bowel. The implant sends out a current that stimulates nerves that control the bladder and bowel, stopping leakage. When someone wants to use the toilet, they deactivate the implant through a hand-held switch. Quarterly financial results for Axonics, released last week, showed a 50 per cent increase in company revenues, compared to the same period last year. The trust has a stock market identification code of BZCNLL9 and a ticker of BBH. Annual charges total 1.1 per cent. Given its specialist nature, it is a fund that should only form a small part of an investor's portfolio. One attractive feature is that it pays a regular dividend, equivalent to around 3.5 per cent per annum. The latest interim dividend of 3.235pence compares to last year's payment of 3.015pence and a share price of £1.74. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
